ArticleMolecular therapy : the journal of the American Society of Gene Therapy2009
Phase I study of H5.020CMV.PDGF-beta to treat venous leg ulcer disease.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Protective Factors and the Pathogenesis of Complications in Diabetes.Endocrine reviews · 2024Review
- Chitosan-Based Dressing as a Sustained Delivery System for Bioactive Cytokines.International journal of molecular sciences · 2023Article
- Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa byMolecular therapy. Methods & clinical development · 2022Article
- Designing electrospun fiber platforms for efficient delivery of genetic material and genome editing tools.Advanced drug delivery reviews · 2022Review
- The Emerging Therapeutic Targets for Scar Management: Genetic and Epigenetic Landscapes.Skin pharmacology and physiology · 2022Review
- Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Advances in surgical applications of growth factors for wound healing.Burns & trauma · 2019Review
- Platelet-derived growth factor-coated decellularized meniscus scaffold for integrative healing of meniscus tears.Acta biomaterialia · 2018Article
- Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.Intractable & rare diseases research · 2017Review
- Effect of sustained PDGF nonviral gene delivery on repair of tooth-supporting bone defects.Gene therapy · 2017Article
- Platelet-Rich Fibrin Lysate Can Ameliorate Dysfunction of Chronically UVA-Irradiated Human Dermal Fibroblasts.Yonsei medical journal · 2016Article
- Regenerative Medicine: Charting a New Course in Wound Healing.Advances in wound care · 2016Review
- A Current View of Functional Biomaterials for Wound Care, Molecular and Cellular Therapies.BioMed research international · 2015Review
- Gene therapy for skin diseases.Cold Spring Harbor perspectives in medicine · 2014Review
- Venous leg ulcerations: a treatment update.Current treatment options in cardiovascular medicine · 2010Article
- Gene Therapy and its Application in Dermatology.Indian journal of dermatologyReview
- Clinical application of growth factors and cytokines in wound healing.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Venous leg ulcers are a prevalent nonhealing wound of the lower extremity. Although topically applied growth factors successfully improve wound repair in animal studies, similar studies on humans with venous leg ulcers have not been successful. This study was designed to evaluate the acute safety and biologic feasibility of peri-ulcer injection of a replication-incompetent adenoviral construct expressing platelet-derived growth factor-beta (PDGF-beta). In this phase I study, we demonstrate the initial safety, feasibility, and biologic plausibility of using H5.020CMV.PDGF-beta to treat venous leg ulcer disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.